Business & Industry News Channel
The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford.
Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to
The trial design is based upon strong scientific evidence supporting the role of the Bruton's tyrosine kinase (BTK) pathway in